Zacks Investment Research Lowers Bayer (BAYRY) to Sell

Bayer (OTCMKTS:BAYRY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

According to Zacks, “Bayer’s earnings beat estimates and revenues declined year over year in the fourth quarter of 2017.  During the fourth quarter of 2017, the Crop Science business reported declined mainly due to the situation in the Brazilian crop protection business. The company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Bayer’s dependence on its pharmaceutical segment for growth remains a concern. Bayer’s shares have underperformed the industry in the past one year. However, as part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell its entire Crop Science businesses to BASF. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions.”

How to Become a New Pot Stock Millionaire

Separately, ValuEngine cut shares of Bayer from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd.

Bayer (BAYRY) traded up $0.07 during trading hours on Tuesday, hitting $28.96. 138,678 shares of the stock traded hands, compared to its average volume of 425,750. Bayer has a 12-month low of $27.80 and a 12-month high of $35.41. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.01 and a current ratio of 1.51. The stock has a market cap of $97,480.87, a PE ratio of 19.40, a price-to-earnings-growth ratio of 1.88 and a beta of 1.20.

Bayer (OTCMKTS:BAYRY) last posted its earnings results on Wednesday, February 28th. The company reported $0.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.11. Bayer had a net margin of 10.84% and a return on equity of 22.39%. The firm had revenue of $10.12 billion during the quarter. equities research analysts expect that Bayer will post 2.38 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers Bayer (BAYRY) to Sell” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thestockobserver.com/2018/03/20/zacks-investment-research-lowers-bayer-bayry-to-sell.html.

About Bayer

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Get a free copy of the Zacks research report on Bayer (BAYRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply